A first-person account of going through whole-genome sequencing and what it reveals — both scientifically and personally — about the promise and limitations of genomic medicine at the consumer level.

An early forecast that the NGS clinical sequencing market would surpass $1 billion by 2015 — identifying oncology and prenatal testing as the largest opportunities, and FDA clearance and payer reimbursement as the key inflection points for widespread adoption.